


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A virus genome having a *pol* gene that encodes an RNA-dependent polymerase, the genome being modified to produce an attenuated virus, the genome further comprising at least one *pol* gene modification that causes the polymerase to have increased fidelity as compared with a polymerase from a virus genome that does not comprise the *pol* gene modification, wherein the increased fidelity ~~which~~ results in a decreased reversion rate from attenuated virus to non-attenuated virus as compared with an equivalent virus genome without the *pol* gene modification.

2. (Original) The virus genome of claim 1, wherein the RNA-dependent polymerase is an RNA polymerase.

 3. (Original) The virus genome of claim 2, wherein the virus genome is an enterovirus genome.

Claims 4-7: Withdrawn from consideration.


Claim 8: Canceled.

Claim 9: Canceled.

10. (Original) The virus genome of claim 1, wherein the *pol* gene modification comprises a mutation resulting in an alteration of the RNA polymerase active site.

11. (Original) The virus genome of claim 1, having a reversion rate at least two-fold decreased as compared with an equivalent virus without the *pol* gene modification.

12. (Original) A viral vector for delivering a heterologous nucleic acid to a target cell, tissue or organ, comprising the virus genome of claim 1, said genome further comprising at least one cloning site for insertion of an expressible heterologous nucleic acid.



13. (Original) The vector of claim 12, comprising an expressible heterologous nucleic acid encoding an antigenic molecule.

14. (Original) The vector of claim 12, comprising an expressible heterologous nucleic acid encoding a biologically active molecule.

15. (Original) A live, attenuated viral vaccine comprising the virus genome of claim 1.

Claims 16-30: Canceled.